Here are some amendments to the GvHD trial as spelled out

New Post Public Reply Private Reply Replies (1) Message Board
trding trding #135
8,379
Here are some amendments to the GvHD trial as spelled out in the latest 10q. RP touched on some changes in the latest conference, having everyone on the same treatment plan, so they can easier compare results. I really like his method of meeting the experts and coming up with a better game plan, it made me feel we are in good hands here with the future trial designs. Also the slide deck gave as a milestone interim results 2H2019. The total cost of $4M is relatively inexpensive versus mono trial spread out over the trial length of one year, with first primary endpoint measured after 200 days, 100 days of treatment+100 day wait. I see the added value with good results vs low cost, giving a high return to shareholders.

Phase 2 Trial for Graft-versus-Host Disease
This Phase 2 multi-center100-day study with 60 patients is designed to evaluate the feasibility of the use of leronlimab (PRO 140) as an add-on therapy to standard graft-versus-host disease (“GvHD”) prophylaxis treatment for prevention of acute GvHD in adult patients with acute myeloid leukemia (“AML”) or myelodysplastic syndrome (“MDS”) undergoing allogeneic hematopoietic stem cell transplantation (“HST”). Enrollment of the first patient was announced in May of 2017. On October 5, 2017, the Company announced that the FDA had granted orphan drug designation to leronlimab (PRO 140) for the prevention of GvHD. In March 2018, we announced that the Independent Data Monitoring Committee (“IDMC”) for leronlimab (PRO 140) Phase 2 trial in GvHD had completed a planned interim analysis of trial data on the first 10 patients enrolled. Following this review of data from the first 10 patients in the Phase 2 trial, the Company filed amendments to the protocol with the FDA. The amendments included switching the pretreatment conditioning regimen from aggressive myeloablative (“MA”) conditioning to a reduced intensity conditioning (“RIC”), and switching from a blinded one-for-one randomized placebo-controlled design to an open-label design under which all enrollees receive leronlimab (PRO 140). The amendments also provide for a 100% increase in the dose of leronlimab (PRO 140), to 700 mg, to more closely mimic preclinical dosing. The next review of data by the IDMC will occur following enrollment of 10 patients under the amended protocol after each patient has been dosed for 30 days. Management estimates the cost of this trial to be approximately $3.5 to $4 million.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vylor's $3 Billion Buyback: A Long-Term Bet

Updated Category News Views 0

Pumping Confidence with a Massive Buyback Vylor's big move to throw $3 billion into a share buyback isn't about short-term antics. This company's doubling down on long-term value creation, making sure every stakeholder knows they're in for the long haul. It's a gutsy move but what this step really tells us is, they've got faith in the business and a balance sheet that can...

Continue Reading
45% of Firms Lack AI Integration Leadership

Updated Category News Views 4

Unclaimed Territory in the AI Era Mid-market businesses have leapt onto the AI bandwagon with wild enthusiasm, yet they're stumbling in the dark when it comes to making it work. The latest findings from Lever Talent, a talent evolution firm, spill the beans that about 45% of these outfits lack a designated maestro to lead the AI-human orchestra. Without a clear conductor,...

Continue Reading
Quest Diagnostics Boosts 2026 Guidance Amid Growth

Updated Category News Views 1

Quest's Earnings Boost: A Closer Look There's no denying Quest Diagnostics (NYSE:DGX) has slipped into high gear this past quarter. Revenues for the third quarter landed at $3.10 billion—a tidy 10% lift from the previous year. With a reported diluted EPS of $2.78 jumping a whopping 28.7%, it's no wonder the folks at Quest decided to raise their guidance for the full...

Continue Reading
MADD Calls for Smart Halloween Celebrations

Updated Category News Views 4

Deadly Halloween Roads Demand Attention Ah, Halloween—a night filled with sugar-charged kids, creative costumes, and a whole horde of potential hazards on the roads. If you're thinking about heading out to enjoy some spooky festivities, it's time to heed a serious warning. MADD, or Mothers Against Drunk Driving, is sounding the alarm as Halloween looms. It's one of the...

Continue Reading
Blokees Unveils 900+ Toys at China Expo, Eyes Growth

Updated Category News Views 3

Toy Titans and Strategic Prowess Swinging into Shanghai with the enthusiasm of a kid in a candy store, Blokees laid out a dazzling array of over 900 products at the 2026 China Toy Expo. Showing off its model kits and BLOKEES WHEELS, it's clear the company's firing on all cylinders, hell-bent on driving competitiveness like a rookie trying to prove their worth in a...

Continue Reading
Unpacking the Sonic NEXT S13: A Toolbox Evolution

Updated Category News Views 3

An All-in-One Solution Rolls In Listen up, gearheads and wrench-turners. Sonic Tools USA isn’t messing around with their newest release, the Sonic NEXT S13 toolbox. If you're tired of wrestling stubborn storage or losing track of your tools, this might just be what the shop ordered. Built to endure the tough grind of workshops from aviation to auto repair, the S13 is...

Continue Reading
S&T Bancorp Hits Record Highs in Q3 2026

Updated Category News Views 5

Surpassing Expectations with Record Metrics Well, if it isn’t another stellar quarter for S&T Bancorp (NASDAQ:STBA). The folks over in Indiana, PA, just threw down some serious numbers. The third quarter of 2026 saw net income climbing to $38.6 million, up from $36.6 million last quarter. That's a decent hike if you ask me. But what really stole the spotlight here was...

Continue Reading
Sony's Game-Changing Sensor Reshapes Medical Endoscopy

Updated Category News Views 5

In a world where medical tech innovation can make the difference between life and death, Sony’s latest feat will turn some heads in the healthcare industry. This ain’t about another PlayStation release; we’re talking the IMX742 CMOS image sensor crafted for single-use endoscopes. As far as breakthroughs go, the microscopic square sensor packs a surprising punch by...

Continue Reading
Körber-NAiSE Alliance Spurs Change in Fleet Management

Updated Category News Views 6

Revving Up the Intralogistics Engine Körber's move to grab a slice of NAiSE isn't just another acquisition. It's like turbocharging an already decent engine, propelling intralogistics into a new gear. For those not in the know, Körber's fame in the realm of supply chain solutions isn't just about size; it's about precision and innovation. And NAiSE? Think of them as the...

Continue Reading
Elanco's Strategic Shift: Jamie Preston Takes the Helm

Updated Category News Views 6

Elanco's Bold HR Transition: A New Leader Steps Up Well, here's a shake-up that might just turn a few heads in the corporate world. Elanco Animal Health, the outfit with the ticker NYSE:ELAN that many have their eyes on, is shuffling its HR deck, bringing in Jamie Preston from Eli Lilly to take charge as the new Chief People Officer. Mark November 3rd on your calendars;...

Continue Reading

Top 5 Most Recently Viewed Articles

Itaú Unibanco's Upcoming Interactive Meeting You Shouldn't Miss

Updated Category News Views 166

Join the Interactive Meeting for Itaú Unibanco's 3Q25 Results Itaú Unibanco is excited to announce an upcoming interactive meeting scheduled for November 5, 2025, at 8 a.m. (EST) and 10 a.m. (Brasília time). The meeting will present the 3Q25 results both in Portuguese and English, ensuring that a wide audience can participate and engage. Event Details and Participation...

Continue Reading
Defense Manufacturing Faces Significant Shifts Amid Policy Changes

Updated Category News Views 97

Reactions to Recent Defense Policies Defense stocks took a notable downturn as significant policy changes were announced regarding U.S. defense contractors. Investors reacted sharply following directives aimed at curtailing dividends and share buybacks across the defense sector. The policies come amid concerns over industry practices and investment priorities. Market...

Continue Reading
Strategic Leadership Moves: JTS Health Partners Welcomes Kevin Smith

Updated Category News Views 186

JTS Health Partners Expands Leadership Team with Kevin Smith JTS Health Partners is proud to announce the appointment of Kevin Smith as the new Senior Vice President of RCM Transformation, Client Services, and Solutions. This leadership role has been strategically created to facilitate the organization's robust growth and ensure excellence in client service. Kevin’s...

Continue Reading
Primo Brands Shareholders Face Urgent Deadline for Class Action

Updated Category News Views 185

Overview of the Class Action Lawsuit Against Primo Brands Primo Brands Corporation (NYSE: PRMB) is currently embroiled in a significant class action lawsuit alleging securities fraud as investors scramble against a pressing January 12, 2026, deadline. This situation arises from claims that the company provided misleading information regarding their merger integration,...

Continue Reading
TKM Grupp AS Enhances Car Trade Operations in Lithuania

Updated Category News Views 278

Revamping Car Trade Operations in Lithuania TKM Grupp AS has taken significant steps to streamline its car trade division by consolidating operations under its wholly-owned subsidiary, TKM Auto OÜ. This strategic move aims to enhance operational efficiency and brand independence within its portfolio. The recent announcements shed light on the exciting developments that...

Continue Reading